Delivery Order SPE2DB25D3020-SPE2DB25FWKBS
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Glatiramer 40 mg/ml syringes, valued at $5,083.61. This competitively awarded, firm fixed-price delivery order has an ultimate completion date of August 18, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a continuation of the agency's pharmaceutical procurement strategy through established contract vehicles....
- The Defense Logistics Agency awarded a delivery order valued at $2,930.01 to AmerisourceBergen Drug Corp for Glatiramer 40 mg/mL syringes. This competitively awarded, firm fixed-price delivery order was issued on July 21, 2025, with an ultimate completion date of July 22, 2025. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate office. This delivery order represents a child contract under a larger indefinite...
- The Defense Logistics Agency awarded a $3,666.66 delivery order contract to Amerisourcebergen Drug Corporation for the supply of 4562084498, Glatiramer 40 mg/ml syringes. As the prime contractor, Amerisourcebergen will deliver the pharmaceutical products to a location in Conshohocken, Pennsylvania by September 8, 2023 under a firm fixed price arrangement. No subcontractors or set aside designations were indicated. The Defense Logistics Agency functions to support military readiness by...
- The Defense Logistics Agency awarded a $4,879.96 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 40mg/mL glatiramer syringes. As the prime contractor, Amerisourcebergen will deliver the pharmaceutical products to its Conshohocken, Pennsylvania facility by August 3, 2023 to support DLA's medical supply needs. No subcontractors or set aside designations were indicated. DLA manages the global supply chain for the Department of Defense, ensuring troops have the medical...
- The Defense Logistics Agency Troop Support Medical awarded a $5,664.24 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 40 mg/ml syringes of glatiramer. Performance will take place in Conshohocken, Pennsylvania over July 26-27, 2023. Amerisourcebergen Corporation is the parent company of Amerisourcebergen Drug Corporation, which will fulfill the order for this pharmaceutical product. No set aside designation or subcontractors were indicated. The Defense Logistics...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The contract is for the delivery of glatiramer 40 mg/ml syringes, a specialty pharmaceutical product, with a potential value of $2,832.12. It is a firm fixed price delivery order contract with a completion date of February 6, 2024. Amerisourcebergen Drug Corp is...
- The Defense Logistics Agency Troop Support Medical awarded a $15,409.35 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 40 mg/ml syringes of glatiramer, to be delivered from its Conshohocken, Pennsylvania facility by August 29, 2023. Amerisourcebergen Corporation is the parent company of Amerisourcebergen Drug Corporation. No subcontractors or set aside designations were identified. This order is likely associated with the DLA's stocking and distribution of...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,911.09 firm fixed-price delivery order is for the supply of GLATIRAMER 40 MG/ML SYRINGEML, a medication, with an ultimate completion date of March 27, 2025. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing...
- This federal contract award was made by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical company Amerisourcebergen Corporation. The contract is a firm fixed price delivery order for the pharmaceutical product Glatiramer 40 mg/mL syringe. The award has a ceiling value of $2,832.12 and an ultimate completion date of March 27, 2024. Amerisourcebergen Drug Corp holds an Indefinite Delivery Contract (IDC) with DLA,...
- This federal contract was awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The contract is for the delivery of Glatiramer 40 mg/ml syringes, a pharmaceutical product, with a potential value of $2,832.12. The contract is a firm fixed price delivery order with a completion date of January 5, 2024. No set-aside designation was used for this award....
- SPE2DB25D3020Indefinite Delivery Contract
- SPE2DB25D3020-SPE2DB25FWKBSDelivery Order
The Defense Logistics Agency awarded a $6,973.17 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Glatiramer 40 mg/ml syringes, with an ultimate completion date of August 19, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The parent IDC enables the company to supply a comprehensive range of pharmaceutical products and medical supplies globally, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. This delivery order for Glatiramer, a disease-modifying therapy used in neurological treatment, exemplifies the company's role in fulfilling specialized pharmaceutical requirements for the Defense Health Agency and broader federal healthcare systems through a flexible contract vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.0k | 8/18/25 |